Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) EBT: 2016-2024

Historic EBT for Cidara Therapeutics (CDTX) over the last 9 years, with Dec 2024 value amounting to -$170.3 million.

  • Cidara Therapeutics' EBT fell 435.78% to -$83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$184.8 million, marking a year-over-year decrease of 361.27%. This contributed to the annual value of -$170.3 million for FY2024, which is 579.40% down from last year.
  • Per Cidara Therapeutics' latest filing, its EBT stood at -$170.3 million for FY2024, which was down 579.40% from -$25.1 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' EBT registered a high of -$25.1 million during FY2023, and its lowest value of -$170.3 million during FY2024.
  • For the 3-year period, Cidara Therapeutics' EBT averaged around -$76.2 million, with its median value being -$33.3 million (2022).
  • As far as peak fluctuations go, Cidara Therapeutics' EBT surged by 41.11% in 2021, and later tumbled by 579.40% in 2024.
  • Yearly analysis of 5 years shows Cidara Therapeutics' EBT stood at -$72.1 million in 2020, then skyrocketed by 41.11% to -$42.5 million in 2021, then rose by 21.56% to -$33.3 million in 2022, then increased by 24.76% to -$25.1 million in 2023, then slumped by 579.40% to -$170.3 million in 2024.